FiercePharma

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes Forxiga, a once-daily oral agent, provides ...
FierceBiotech

FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes

AstraZeneca and Bristol-Myers Squibb Company today announced that the European Commission has approved FORXIGA™ (dapagliflozin) tablets for the treatment of type 2 diabetes in the European Union (EU).
FiercePharma

Forxiga Receives Regulatory Approval in Japan for the Treatment of Type 2 Diabetes

AstraZeneca today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved FORXIGA® (dapagliflozin in 5 and 10 mg tablets), a sodium-glucose cotransporter 2 (SGLT2) inhibitor ...
Business Wire

Forxiga™ (Dapagliflozin), erster SGLT-2-Hemmer der neuen Substanzklasse mit insulinunabhängiger Wirkung jetzt in der Europäischen Union zur Behandlung des Typ-2-Diabetes ...

PARIS und LONDON--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) und AstraZeneca (NYSE: AZN) gaben heute bekannt, dass die Europäische Kommission Forxiga™ (Dapagliflozin)-Tabletten für die ...
AOL

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in

PRINCETON, N.J. and LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYS: BMY) and AstraZeneca (NYS: AZN) today announced that the European Commission has approved Forxiga ™ (dapagliflozin) ...
Medscape

EU Approves Dapagliflozin for Kidney Disease, Regardless of Diabetes

Dapagliflozin (Forxiga) has been approved for use in the European Union to treat adults with chronic kidney disease who do not have diabetes. It is the first agent from the sodium-glucose ...
Business Wire

Forxiga™ (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes

Forxiga, a once-daily oral agent, provides physicians with a new option to improve glycaemic control as monotherapy in metformin-intolerant patients or combination therapy Reduction of weight and ...